4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000899243-17-021281
Chief Executive Officer sold 75,795 shares at an average $20.25 ($1,534,869)
- Chief Executive Officer acquired 23,414 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Novak Rodger · Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2017-08-28 | Exercise or conversion : show line 1 in the form | +17,692 | $1.81 | $32,023 | 1,232,697 | D |
| 2017-08-28 | Sale : show line 2 in the form | −17,692 | $20.06 | $354,919 | 1,215,005 | D |
| 2017-08-30 | Exercise or conversion : show line 3 in the form | +5,722 | $1.81 | $10,357 | 1,220,727 | D |
| 2017-08-30 | Sale : show line 4 in the form | −58,103 | $20.31 | $1,179,950 | 1,162,624 | D |
| Open-market sales · 75,795 sh · avg $20.25 · $1,534,869 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2017-08-28 | Exercise or conversion : show line 5 in the form Stock Options (Right to Buy) | −17,692 | 50,401 | D |
| 2017-08-30 | Exercise or conversion : show line 6 in the form Stock Options (Right to Buy) | −5,722 | 44,679 | D |
Loading xslF345X03/doc4.xml…